Allergy Asthma Clin Immunol: 不良睡眠与屋尘螨过敏性鼻炎高度相关

2017-08-21 AlexYang MedSci原创

睡眠障碍在患有过敏症病人中常见报道。最近,有研究人员鉴定了睡眠障碍与屋尘螨(HDM)呼吸道过敏原在常规临床实践的舌下过敏原免疫疗法(SLIT)起始时的关系。研究人员设计的研究为前瞻性的、代表性的和观察性的研究,时间在2014年11月到2015年3月,地点在189个法国试验地点,总共包括了1750名HDM过敏的且开始SLIT治疗的病人,排除了年龄小于5岁的和之前进行过HDM过敏原抗原免疫治疗(AIT

睡眠障碍在患有过敏症病人中常见报道。最近,有研究人员鉴定了睡眠障碍与屋尘螨(HDM)呼吸道过敏原在常规临床实践的舌下过敏原免疫疗法(SLIT)起始时的关系。研究人员设计的研究为前瞻性的、代表性的和观察性的研究,时间在2014年11月到2015年3月,地点在189个法国试验地点,总共包括了1750名HDM过敏的且开始SLIT治疗的病人,排除了年龄小于5岁的和之前进行过HDM过敏原抗原免疫治疗(AIT)的病人。睡眠障碍通过自我进行的调查问卷进行评估。研究人员将调整了肥胖、抽烟状态、哮喘控制和鼻塞的逻辑回归模型用来研究过敏性鼻炎(AR)分类与睡眠障碍的关系。研究结果表明,在募集的1786名参与者中,1750(907名成年人和843名儿童)组成了分析群体。大多数参与者(73.5%成年人和65.8%儿童)报道了睡眠障碍引起了他们向医师咨询。最为常见的睡眠并发症有较差的睡眠质量(50.3%成年人和37.3%儿童)、打鼾(分别为48.1%和41.4%)、半夜痛醒(分别为37.6%和28.2%)。另外,有27%的成年人和24.7%的儿童报道了难入睡眠。患有重度AR的成年人和儿童经历了比患有轻微或者中等

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1711172, encodeId=ed001e1117288, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Sep 27 07:55:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977119, encodeId=b32219e7119ce, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Thu Mar 01 17:55:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046870, encodeId=661520468e0ad, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Apr 20 04:55:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237397, encodeId=e50b23e39747, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Aug 26 14:36:44 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329008, encodeId=c3fb132900851, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Aug 23 11:55:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348573, encodeId=f96913485e399, content=<a href='/topic/show?id=54c24e71237' target=_blank style='color:#2F92EE;'>#屋尘螨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47712, encryptionId=54c24e71237, topicName=屋尘螨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Aug 23 11:55:00 CST 2017, time=2017-08-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1711172, encodeId=ed001e1117288, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Sep 27 07:55:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977119, encodeId=b32219e7119ce, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Thu Mar 01 17:55:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046870, encodeId=661520468e0ad, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Apr 20 04:55:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237397, encodeId=e50b23e39747, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Aug 26 14:36:44 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329008, encodeId=c3fb132900851, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Aug 23 11:55:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348573, encodeId=f96913485e399, content=<a href='/topic/show?id=54c24e71237' target=_blank style='color:#2F92EE;'>#屋尘螨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47712, encryptionId=54c24e71237, topicName=屋尘螨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Aug 23 11:55:00 CST 2017, time=2017-08-23, status=1, ipAttribution=)]
    2018-03-01 skhzy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1711172, encodeId=ed001e1117288, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Sep 27 07:55:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977119, encodeId=b32219e7119ce, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Thu Mar 01 17:55:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046870, encodeId=661520468e0ad, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Apr 20 04:55:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237397, encodeId=e50b23e39747, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Aug 26 14:36:44 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329008, encodeId=c3fb132900851, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Aug 23 11:55:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348573, encodeId=f96913485e399, content=<a href='/topic/show?id=54c24e71237' target=_blank style='color:#2F92EE;'>#屋尘螨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47712, encryptionId=54c24e71237, topicName=屋尘螨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Aug 23 11:55:00 CST 2017, time=2017-08-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1711172, encodeId=ed001e1117288, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Sep 27 07:55:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977119, encodeId=b32219e7119ce, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Thu Mar 01 17:55:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046870, encodeId=661520468e0ad, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Apr 20 04:55:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237397, encodeId=e50b23e39747, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Aug 26 14:36:44 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329008, encodeId=c3fb132900851, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Aug 23 11:55:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348573, encodeId=f96913485e399, content=<a href='/topic/show?id=54c24e71237' target=_blank style='color:#2F92EE;'>#屋尘螨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47712, encryptionId=54c24e71237, topicName=屋尘螨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Aug 23 11:55:00 CST 2017, time=2017-08-23, status=1, ipAttribution=)]
    2017-08-26 往日如昨

    学习了谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1711172, encodeId=ed001e1117288, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Sep 27 07:55:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977119, encodeId=b32219e7119ce, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Thu Mar 01 17:55:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046870, encodeId=661520468e0ad, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Apr 20 04:55:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237397, encodeId=e50b23e39747, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Aug 26 14:36:44 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329008, encodeId=c3fb132900851, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Aug 23 11:55:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348573, encodeId=f96913485e399, content=<a href='/topic/show?id=54c24e71237' target=_blank style='color:#2F92EE;'>#屋尘螨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47712, encryptionId=54c24e71237, topicName=屋尘螨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Aug 23 11:55:00 CST 2017, time=2017-08-23, status=1, ipAttribution=)]
    2017-08-23 膀胱癌
  6. [GetPortalCommentsPageByObjectIdResponse(id=1711172, encodeId=ed001e1117288, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Sep 27 07:55:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977119, encodeId=b32219e7119ce, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Thu Mar 01 17:55:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046870, encodeId=661520468e0ad, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Apr 20 04:55:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237397, encodeId=e50b23e39747, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Aug 26 14:36:44 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329008, encodeId=c3fb132900851, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Aug 23 11:55:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348573, encodeId=f96913485e399, content=<a href='/topic/show?id=54c24e71237' target=_blank style='color:#2F92EE;'>#屋尘螨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47712, encryptionId=54c24e71237, topicName=屋尘螨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Aug 23 11:55:00 CST 2017, time=2017-08-23, status=1, ipAttribution=)]

相关资讯

Allergy Asthma Immunol Res:鼻纤维素粉在过敏性鼻炎对症治疗中的功效研究

鼻纤维素粉(NCP)可以阻止过敏原结合到鼻粘膜,从而可以减少尘螨敏感儿童过敏性鼻炎(AR)症状的发生。最近,有研究人员评估了NCP在鼻气流限制临床症状改善中的功效和鼻腔炎症细胞中的响应。研究招募了年龄在6-18岁的且患有尘螨敏感过敏性鼻炎的儿童。在4周磨合期结束后,研究人员进行了NCP或者安慰剂处理,1个鼻孔喷一次,一天3次,持续时间为4周。屋尘螨(Der p)鼻黏膜激发试验(NPT)在处理前后分

Clin Mol Allergy:在意大利,过敏专家关于对报销治疗季节性过敏性鼻炎草花粉片观点的调查

对经典的皮下注射免疫疗法来说,舌下免疫治疗(SLIT)是一种可行的免疫疗法来治疗呼吸道过敏症,并且在欧洲越来越流行。然而,报销的缺乏也许限制了它的应用。在2015年,5-草花粉药片被欧洲医药机构授权批准来治疗草-花粉引起的鼻炎,并且在意大利得到了全额报销的批准。最近,有研究人员评估了可报销5-草花粉片可利用后,过敏专家的选择情况。研究人员利用一个包含6个问题的多项选择调查问卷来评估专家的选择,并将

Mol Med Rep:TNFSF4与BLK基因多样性的关系以及对过敏性鼻炎的易感性

过敏性鼻炎(AR)是上呼吸道常见的炎症疾病。最近的证据表明,肿瘤坏死因子受体超家族4(TNFSF4)和B淋巴细胞激酶(BLK)基因间的互作也许在决定免疫失常方面的T和B细胞具有协同影响,并通过核转录因子κB信号通路。最近,有研究人员在中国人口中对AR敏感的人群中评估了TNFSF4和BKL基因中特异性单核苷酸多态(SNPs)的潜在联系。该研究是一个基于群体的且具有案例-对照的研究,包括了600名AR

Rhinology:在一个过敏性鼻炎小鼠模型中,过敏性炎症可以被过敏原诱导的类型2固有淋巴细胞加重

类型2固有淋巴细胞(ILC2s)代表了一种新的先天性效应白细胞类群,并且可以调节类型2免疫响应。然而,ILC2s对过敏性鼻炎(AR)的作用到目前为止仍旧还未鉴定。为了评估过敏原诱导的ILC2s在实验性AR中潜在的存在和作用,研究人员利用卵清蛋白(OVA)和氢氧化铝建立了一个AR小鼠模型,并从小鼠鼻相关淋巴组织(NALT)中筛选和纯化OVA诱导的ILC2s。然后,研究人员评估了在细胞培养中评估了IL

Am J Rhinol Allergy:过敏性鼻炎的症状与减少的健康生活品质的关系

目前,特异性的过敏性鼻炎症状对病人生活品质(QOL)的影响仍旧未知。最近,有研究人员探究了过敏性鼻炎鼻骨和鼻外症状对健康相关的QOL的关系。该横断面研究总共包括了150名年龄大于18岁的参与者,并且这些参与者患有永久性过敏性鼻炎。健康相关的QOL通过利用来自5维EuroQol QOL调查(EO-5D)的视觉模拟量表(VAS)来进行测量。利用22项中鼻结果测试(SNOT-22)来对鼻骨和鼻外症状的严

PLoS One:患有过敏性鼻炎的病人,牙外伤风险增加

过敏性鼻炎(AR)与影响牙齿的各种发展问题相关。最近,有研究人员调查了在台湾地区人口中,是否AR与牙外伤(TDIs)风险的增加相关。研究人员利用台湾地区医疗健康研究数据库(NHIRD)进行了一项巢式病例对照研究。他们比较了患有过敏性鼻炎人群和与之匹配的不患有过敏性鼻炎人群的相关参数。在研究中,他们还确定了新的TDI病例。为了比较TDI在研究群体中的风险,研究人员利用Cox比例回归分析和风险比(HR